What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2025-12-15 compared with 2025-09-15 · 115 added, 65 removed, 418 unchanged (30% of the section changed)

42 unchanged sentences

Three Months Ended

October 31, Six Months Ended

2025 2024 2025 2024

Oncology revenue $ 15,035 $ 13,489 $ 29,030 $ 27,550

6 unchanged sentences

Total costs and operating expenses 14,850 12,757 29,372 25,489

(Loss) income from operations ( 527 ) 1,329

Income (loss) from operations 185 732 ( 342 ) 2,061

Other income, net 70 7 145 11

(Loss) income before provision for income taxes ( 452 ) 1,334

Income (loss) before provision for income taxes 255 739 ( 197 ) 2,072

Provision for income taxes 18 11 33 31

Net (loss) income $ ( 466 ) $ 1,313

Net income (loss) $ 237 $ 728 $ ( 230 ) $ 2,041

net loss attributable to noncontrolling interest 31 — 61 —

Net (loss) income attributable to Company's common shares $ ( 436 ) $ 1,313

Net (loss) income per common share outstanding

Net income (loss) attributable to Company's common shares $ 268 $ 728 $ ( 169 ) $ 2,041

Net income (loss) per common share outstanding

basic $ 0.02 $ 0.05 $ ( 0.01 ) $ 0.15

17 unchanged sentences

Balance July 31, 2025 13,908,754 $ 14 120,333 $ ( 708 ) $ 84,560 $ 30 $ ( 80,358 ) $ 3,538

Stock-based compensation — — — — 218 31 — 249

Issuance of common stock on exercise of stock options 97,905 — — — 207 — — 207

Net income — — — — — — 237 237

Balance October 31, 2025 14,006,659 $ 14 120,333 $ ( 708 ) $ 84,985 61 $ ( 80,121 ) $ 4,231

Common Stock Treasury Stock Additional

1 unchanged sentence

Deficit Total

Stockholders'

Stockholders' Equity/

Shares Amount Shares Amount

3 unchanged sentences

Balance July 31, 2024 13,714,099 $ 14 120,333 $ ( 708 ) $ 83,642 $ ( 83,280 ) $ ( 332 )

Stock-based compensation — — — — 9 — 9

Issuance of common stock on exercise of stock options 105,137 — — 276 — 276

Net income — — — — — 728 728

Balance October 31, 2024 13,819,236 $ 14 120,333 ( 708 ) $ 83,927 $ ( 82,552 ) $ 681

The accompanying notes are an integral part of these condensed consolidated financial statements.

2 unchanged sentences

(Dollars in Thousands)

Three Months Ended

Six Months Ended

Operating activities:

Net (loss) income $ ( 230 ) $ 2,041

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

Stock-based compensation 457 267

1 unchanged sentence

Loss on disposal of equipment 20 —

Gain on termination of operating lease ( 9 ) —

Operating lease right-of use assets 734 583

7 unchanged sentences

Deferred revenue ( 3,105 ) ( 1,874 )

Net cash provided by operating activities 600 311

Net cash (used in) provided by operating activities ( 1,135 ) 28

Investing activities:

4 unchanged sentences

Finance lease payments ( 77 ) ( 74 )

Net cash used in financing activities ( 14 ) ( 37 )

Increase in cash 540 274

Net cash provided by financing activities 154 202

(Decrease) Increase in cash ( 1,269 ) 136

Cash at beginning of period 9,785 2,618

17 unchanged sentences

("Corellia").

For the three months ended July 31, 2025 and 2024, there were no revenues earned by these subsidiaries.

For the three and six months ended October 31, 2025 and 2024, there were no revenues earned by these subsidiaries.

The Company’s foreign subsidiaries' functional currency is the U.S.

16 unchanged sentences

Significant Accounting Policies

The significant accounting policies used in the preparation of these condensed consolidated financial statements are disclosed in our 2025 Annual Report and there have been no changes to the Company's significant accounting policies during the three months ended July 31, 2025.

The Company's liquidity needs have typically arisen from the funding of its research and development programs and the launch of new products and services, working capital requirements, and other strategic initiatives.

1 unchanged sentence

In the past, the Company has also received proceeds from certain private placements and public offerings of our securities.

For the three months ended July 31, 2025, the Company had a net loss of approximately $ 466,000 , an accumulated deficit of approximately $ 80.4 million negative working capital of $ 1.7 million and cash of $ 10.3 million.

For the six months ended October 31, 2025, the Company had a net loss of approximately $ 237,000 , an accumulated deficit of approximately $ 80.1 million, negative working capital of $ 809,000 and cash of $ 8.5 million.

Despite the negative working capital, we believe that our cash on hand, together with expected cash flows from operations, are adequate to fund operations through at least the next twelve months from the filing of this report.

4 unchanged sentences

Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s common stock options.

A reconciliation of net income and number of shares used in computing basic and diluted earnings per share was as follows:

A reconciliation of net income (loss) and number of shares used in computing basic and diluted earnings per share was as follows:

Three Months Ended

October 31, Six Months Ended October 31,

(Dollars in Thousands) 2025 2024 2025 2024

9 unchanged sentences

Diluted net income (loss) per share $ 0.02 $ 0.05 $ ( 0.01 ) $ 0.15

The following table reflects the total potential common stock instruments outstanding at July 31, 2025 and 2024 including those that could have an effect on the future computation of dilution per common share, had their effect not been anti-dilutive.

The following table reflects the total potential common stock instruments outstanding at October 31, 2025 and 2024 including those that could have an effect on the future computation of dilution per common share, had their effect not been anti-dilutive.

Total common stock equivalents 2,420,026 907,979

68 unchanged sentences

The ASU is effective retrospectively for fiscal years beginning after December 15, 2024, with early adoption permitted.

The Company adopted this ASU as of May 1, 2025 and the impact on its financial statements was not material.

The Company adopted this ASU as of May 1, 2025 and it has been included in the required disclosures in our financial statements since.

In November 2024 and January 2025, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" (Subtopic 220-40) "Disaggregation of Income Statement Expenses" and ASU 2025-01 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" (Subtopic 220-40):

5 unchanged sentences

Accounts receivable and unbilled services were as follows (in thousands):

July 31, 2025 April 30, 2025 May 1, 2024

October 31, 2025 April 30, 2025 May 1, 2024

Accounts receivable $ 5,381 $ 6,835 $ 4,886

8 unchanged sentences

Reversal for amounts subsequently collected —

Ending balance July 31, 2025 $ ( 1,000 )

Ending balance October 31, 2025 $ ( 1,013 )

Deferred revenue was as follows (in thousands):

July 31, 2025 April 30, 2025 May 1, 2024

October 31, 2025 April 30, 2025 May 1, 2024

Deferred revenue $ 12,338 $ 15,443 $ 12,094

1 unchanged sentence

Oncology Revenue

The following table represents disaggregated revenue for the three months ended July 31, 2025 and 2024 (in thousands):

The following table represents disaggregated revenue for the three and six months ended October 31, 2025 and 2024 (in thousands):

Three Months Ended

October 31, Six Months Ended October 31,

2025 2024 2025 2024

Pharmacology services $ 14,515 $ 12,498 $ 27,745 $ 25,567

18 unchanged sentences

Property and equipment, net $ 3,951 $ 4,375

Depreciation and amortization expense was $ 358,000 and $ 449,000 for the three months ended July 31, 2025 and 2024, respectively.

Depreciation and amortization expense, excluding expense recorded under finance leases, was $ 320,000 and $ 412,000 for the three months ended July 31, 2025 and 2024, respectively.

As of July 31, 2025 and April 30, 2025, property, plant and equipment included gross assets held under finance leases of $ 1.0 million.

Related depreciation expense was approximately $ 38,000 and $ 37,000 for the three months ended July 31, 2025 and 2024, respectively.

Depreciation and amortization expense was $ 357,000 and $ 399,000 for the three months ended October 31, 2025 and 2024, respectively.

Depreciation and amortization expense, excluding expense recorded under finance leases, was $ 318,000 and $ 362,000 for the three months ended October 31, 2025 and 2024, respectively.

Depreciation and amortization expense was $ 715,000 and $ 848,000 for the six months ended October 31, 2025 and 2024, respectively.

Depreciation and amortization expense, excluding expense recorded under finance leases, was $ 638,000 and $ 774,000 for the six months ended October 31, 2025 and 2024, respectively.

As of October 31, 2025 and April 30, 2025, property, plant and equipment included gross assets held under finance leases of $ 1.0 million.

Related depreciation expense was approximately $ 39,000 and $ 37,000 for the three months ended October 31, 2025 and 2024, respectively, and $ 77,000 and $ 74,000 for the six months ended October 31, 2025 and 2024, respectively.

During the three months ended July 31, 2025, the Company disposed of lab equipment with a cost of $ 44,000 and accumulated depreciation of $ 24,000 as of the disposal date, resulting in a loss on disposal of equipment recorded of $ 20,000 .

During the three months ended July 31, 2024, the Company did not dispose of any equipment.

The Company did no t dispose of any equipment during the three months ended October 31, 2025.

During the three and six months ended October 31, 2024, the Company did no t dispose of any equipment.

Finance Lease

3 unchanged sentences

The present value of the minimum future obligations of $ 368,000 was calculated based on an interest rate of 3.5 %.

Depreciation and amortization expense related to this finance lease was $ 19,000 and $ 18,000 for the three months ended July 31, 2025 and 2024.

Interest on the related finance lease liability was less than $ 1,000 and approximately $ 1,000 for the three months ended July 31, 2025 and 2024, respectively.

Depreciation and amortization expense related to this finance lease was $ 19,000 and $ 18,000 for the three months ended October 31, 2025 and 2024, respectively, and $ 38,000 and $ 36,000 , for the six months ended October 31, 2025 and 2024, respectively.

Interest on the related finance lease liability was approximately $ 1,100 and $ 1,800 for the three months ended October 31, 2025 and 2024, respectively.

Interest on the related finance lease liability was approximately $ 2,400 and $ 3,700 for the six months ended October 31, 2025 and 2024, respectively.

During fiscal year 2022, the Company recognized a finance lease for laboratory equipment.

2 unchanged sentences

At the commencement of the commitment, the present value of the minimum future obligations of $ 370,000 was calculated based on an interest rate of 3.25 %.

Depreciation and amortization expense related to this finance lease was $ 19,000

and $ 19,000 for the three months ended July 31, 2025 and 2024, respectively.

Interest on the related finance lease liability was approximately $ 1,300 and $ 2,000 for the three months ended July 31, 2025 and 2024, respectively.

Depreciation and amortization expense related to this finance lease was $ 20,000 and $ 19,000 for the three months ended October 31, 2025 and 2024, respectively, and $ 39,000 and $ 38,000 , for six months ended October 31, 2025 and 2024, respectively.

Interest on the related finance lease liability was less than $ 1,000 for the three and six months ended October 31, 2025.

Interest on the related finance lease liability was less than $ 1,000 for the three months ended October 31, 2024 and approximately $ 1,900 for the six months ended October 31, 2024.

As noted above, the Company's financing leases are for laboratory equipment.

2 unchanged sentences

Financing lease assets (lab equipment) and lease liabilities related to our current financing leases are as follows (in thousands):

July 31, 2025 April 30, 2025

October 31, 2025 April 30, 2025

Financing lease net asset $ 143 $ 220

10 unchanged sentences

Three Months Ended

October 31, Six Months Ended

2025 2024 2025 2024

General and administrative $ 191 $ ( 95 ) $ 339 $ 90

3 unchanged sentences

Total stock-based compensation expense $ 249 $ 9 $ 457 $ 267

For the three months ended July 31, 2025, stock-based compensation expense for research and development includes approximately $ 30,000 for options granted by the Company's wholly-owned subsidiary, Corellia, to certain of its employees.

The Company has in place a 2021 Equity Incentive Plan and 2010 Equity Incentive Plan as well as the 2023 Global Equity Incentive Plan which is specific to Corellia AI (collectively, the "Plans").

For the three and six months ended October 31, 2025, stock-based compensation expense for research and development includes approximately $ 31,000 and $ 61,000 respectively, for options granted by the Company's wholly-owned subsidiary, Corellia, to certain of its employees.

The Company has in place a 2021 Equity Incentive Plan and 2010 Equity Incentive Plan as well as the 2023 Global Equity Incentive Plan which is specific to Corellia (collectively, the "Plans").

In general, these Plans provide for stock-based compensation to the Company’s employees, directors and non-employees.

5 unchanged sentences

(iii) Restricted Stock Awards;

and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its

employees, directors and non-employees.

and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees.

Total stock awards under the 2021 Equity Plan shall not exceed 2 million shares of common stock.

1 unchanged sentence

Options and Stock Appreciation Rights have a strike price not less than 100 % of the fair market value of the common stock subject to the option or right at the date of grant.

As of July 31, 2025, approximately 342,000 shares were available for issue under this plan.

As of October 31, 2025, approximately 355,000 shares were available for issue under this plan.

2010 Equity Incentive Plan

7 unchanged sentences

After February 2021, no more shares were available to be issued from this plan.

As of July 31, 2025, approximately 885,000 options granted under the 2010 plan were still outstanding.

As of October 31, 2025, approximately 787,000 options granted under the 2010 plan were still outstanding.

2023 Global Equity Incentive Plan

6 unchanged sentences

Stock Option Grants

Black-Scholes and Monte Carlo assumptions used to calculate the fair value of Champions options granted by the Company during the three months ended July 31, 2025 and 2024 were as follows:

Black-Scholes and Monte Carlo assumptions used to calculate the fair value of Champions options granted by the Company during the three and six months ended October 31, 2025 and 2024 were as follows:

Three Months Ended

October 31, Six Months Ended

2025 2024 2025 2024

Expected term in years 0

Risk-free interest rates — %

3.58 % - 3.77 %

4.08 % - 4.50 %

3.58 % - 4.48 %

Volatility — %

59.47 % - 59.57 %

55.65 % - 62.00 %

59.47 % - 62.72 %

Dividend yield — % — % — % — %

The weighted average fair value of stock options granted during the three months ended July 31, 2025 and 2024 was $ 4.33 and $ 3.02 , respectively.

Black-Scholes assumptions used to calculate the fair value of Corellia options granted by Corellia during the three months ended July 31, 2025 and 2024 were as follows:

The weighted average fair value of stock options granted during the three months ended October 31, 2025 and 2024 was $ 0.00 and $ 2.48 , respectively, noting that no options were granted during the three months ended October 31, 2025.

The weighted average fair value of stock options granted during the six months ended October 31, 2025 and 2024 was $ 4.33 and $ 2.49 , respectively.

Black-Scholes assumptions used to calculate the fair value of Corellia options granted by Corellia during the three and six months ended October 31, 2025 and 2024 were as follows:

Three Months Ended

October 31, Six Months Ended

2025 2024 2025 2024

Expected term in years 0 0 6 0

2 unchanged sentences

Dividend yield — % — % — % — %

The weighted average fair value of stock options granted during the three months ended July 31, 2025 was $ 1,364.00 .

There have been no Corellia stock options granted prior to the first quarter of fiscal 2026.

The weighted average fair value of stock options granted during the six months ended October 31, 2025 was $ 1,364.00 .

There have been no Corellia stock options granted prior to the first quarter of fiscal 2026 and no options were granted during the three months ended October 31, 2025.

Due to the absence of an active market for the Corellia's common stock, Corellia utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock.

3 unchanged sentences

Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.

The Company’s stock options activity for the 2021 and 2010 equity incentive plans for the three months ended July 31, 2025 was a s follows:

The Company’s stock options activity for the 2021 and 2010 equity incentive plans for the six months ended October 31, 2025 was a s follows:

Employees Non-

6 unchanged sentences

Forfeited ( 15,125 ) — ( 15,125 ) 7.04

Outstanding, July 31, 2025 2,495,475 36,331 2,531,806 $ 5.81 6.5 $ 3,514,000

Vested and expected to vest as of July 31, 2025 2,495,475 36,331 2,531,806 $ 5.81 6.5 $ 3,514,000

Exercisable as of July 31, 2025 1,504,457 5,625 1,510,082 $ 4.90 4.2 $ 3,259,000

The stock options activity for the Corellia 2023 Global equity incentive plan for the three months ended July 31, 2025 was as follows:

Canceled ( 8,375 ) — ( 8,375 ) 7.13

Outstanding, October 31, 2025 2,383,695 36,331 2,420,026 $ 5.96 6.5 $ 3,726,000

Vested and expected to vest as of October 31, 2025 2,383,695 36,331 2,420,026 $ 5.96 6.5 $ 3,726,000

Exercisable as of October 31, 2025 1,458,663 5,625 1,464,288 $ 5.06 4.4 $ 3,476,000

The remaining unrecognized stock-based compensation expense at October 31, 2025 was $ 3.8 million.

Of this amount, $ 1.2 million relates to time-based awards with a remaining weighted average recognition period of 3.61 years and $ 888,000 related to market based awards with a remaining average recognition period of 2.2 years.

The remaining $ 1.7 million of unrecognized stock-based compensation expense relates to performance-based awards for which expense will only be recognized when it becomes probable that the Company will achieve such defined financial targets.

As of October 31, 2025 , there were 430,000 options that have these performance-based vesting provisions and are subject to forfeiture, in whole or in part, if these performance conditions are not achieved.

Management assesses, on an ongoing basis, the probability of whether the performance criteria will be achieved and, if it is deemed probable, stock-based compensation expense is recognized over the relevant performance period.

The stock options activity for the Corellia 2023 Global equity incentive plan for the six months ended October 31, 2025 was as follows:

Employees Non-

4 unchanged sentences

Granted 300 — 300 1,682.00 9.56

Outstanding, July 31, 2025 300 — 300 $ 1,682.00 9.81 $ 110,000

Vested and expected to vest as of July 31, 2025 300 — 300 $ 1,682.00 9.81 $ 110,000

Exercisable as of July 31, 2025 — — — $ — — $ —

Outstanding, October 31, 2025 300 — 300 $ 1,682.00 9.56 $ 110,000

Vested and expected to vest as of October 31, 2025 300 — 300 $ 1,682.00 9.56 $ 110,000

Exercisable as of October 31, 2025 — — — $ — — $ —

The remaining unrecognized stock-based compensation expense at October 31, 2025 was $ 348,000 .

This amount relates to time-based awards with a remaining weighted average recognition period of 2.55 years

Share Repurchase Program

4 unchanged sentences

The program does not obligate the Company to acquire a minimum number of shares.

As of July 31, 2025, the Company had purchased 120,300 shares of its common stock, at an average price of $ 5.73 per share, totaling approximately $ 708,000 and leaving an available balance of approximately $ 4.3 million authorized by the Board for use in the program as of that date.

As of October 31, 2025, the Company had purchased 120,300 shares of its common stock, at an average price of $ 5.73 per share, totaling approximately $ 708,000 and leaving an available balance of approximately $ 4.3 million authorized by the Board for use in the program as of that date.

The last purchase was made during fiscal year 2024.

7 unchanged sentences

Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date.

Rent expense totaled $ 453,000 for both the three months ended July 31, 2025 and 2024.

Rent expense totaled $ 454,000 for both the three months ended October 31, 2025 and 2024.

Rent expense totaled $ 907,000 for both the six months ended October 31, 2025 and 2024.

The Company considers its facilities adequate for its current operational needs.

2 unchanged sentences

The lease expires in November 2026.

The Company recognized $ 19,000 of rent expense relative to this lease for both the three months ended July 31, 2025 and 2024.

The Company recognized $ 19,000 of rent expense relative to this lease for both the three months ended October 31, 2025 and 2024.

The Company recognized $ 38,000 of rent expense relative to this lease for both the six months ended October 31, 2025 and 2024.

• 1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings.

3 unchanged sentences

This lease expires in February 2029.

The Company recognized $ 422,000 of rent expense relative to this lease for both the three months ended July 31, 2025 and 2024.

The Company recognized $ 422,000 of rent expense relative to this lease for both the three months ended October 31, 2025 and 2024.

The Company recognized $ 843,000 of rent expense relative to this lease for both the six months ended October 31, 2025 and 2024.

• VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings.

The Company executed the lease in November 2022.

The lease expires October 31, 2028.

The Company recognized $ 13,000 of rent expense relative to this lease for both the three months ended July 31, 2025 and 2024.

The lease was set to expire October 31, 2028.

During the three months ended October 31, 2025, the Company exercised its right to terminate the lease early.

The lease will terminate April 30, 2026 and the Company will no longer utilize a physical site in Italy.

As part of this lease modification, the Company recorded a reduction to its right of use asset related to this lease of $ 108,000 .

In addition, the Company recorded a reduction to the current and non-current portions of the related operating lease liabilities of $ 16,000 and $ 101,000 , respectively.

A gain on lease termination of $ 9,000 was recorded.

The Company recognized $ 13,000 of rent expense relative to this lease for both the three months ended October 31, 2025 and 2024.

The Company recognized $ 25,000 of rent expense relative to this lease for both the six months ended October 31, 2025 and 2024.

ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):

July 31, 2025 April 30, 2025

October 31, 2025 April 30, 2025

Operating lease right-of-use assets, net

2 unchanged sentences

Non-current portion of operating lease liabilities 3,744 4,634

As of July 31, 2025, the weighted average remaining operating lease term and the weighted average discount rate were 3.51 years and 5.89 %, respectively.

As of July 31, 2024, the weighted average remaining operating lease term and the weighted average discount rate were 4.49 years and 5.88 %, respectively.

As of October 31, 2025, the weighted average remaining operating lease term and the weighted average discount rate were 3.26 years and 5.83 %, respectively.

As of October 31, 2024, the weighted average remaining operating lease term and the weighted average discount rate were 4.24 years and 5.88 %, respectively.

Future minimum lease payments due each fiscal year as follows (in thousands):

3 unchanged sentences

Present value of minimum lease payments $ 5,269

The composition of total lease cost for three months ended July 31, 2025 and 2024 were as follows (in thousands):

Three Months Ended July 31,

The composition of total lease cost for three and six months ended October 31, 2025 and 2024 were as follows (in thousands):

Three Months Ended October 31, Six Months Ended October 31,

2025 2024 2025 2024

Operating lease costs $ 445 $ 432 $ 885 $ 861

8 unchanged sentences

Consulting Services

During the three months ended July 31, 2025 and 2024, the Company recognized $ 0 and $ 9,000 , respectively, for consulting services provided by an affiliate of a Board member, unrelated to his duty as a Board member.

During the three months ended October 31, 2025 and 2024, the Company recognized $ 0 and $ 6,000 , respectively, for consulting services provided by an affiliate of a Board member, unrelated to his duty as a Board member.

During the six months ended October 31, 2025 and 2024, the Company recognized $ 0 and $ 15,000 , respectively, for consulting services provided by an affiliate of a Board member, unrelated to his duty as a Board member.

Such amounts are included in general and administrative expenses in the accompanying condensed consolidated statements of operations.

As of July 31, 2025, $ 0 was due to this related party.

As of October 31, 2025, $ 0 was due to this related party.

Commitments and Contingencies

7 unchanged sentences

Some of these arrangements also set forth an annual minimum royalty due regardless of tumor models used for sale.

For the three months ended July 31, 2025 and 2024, we have recognized approximately $ 39,000 and $ 81,000 , respectively, in expense related to these royalty arrangements.

For the three months ended October 31, 2025 and 2024, we have recognized approximately $ 134,000 and $ 104,000 , respectively, in expense related to these royalty arrangements.

For the six months ended October 31, 2025 and 2024, we have recognized approximately $ 173,000 and $ 185,000 , respectively, in expense related to these royalty arrangements.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements